74. 下垂体性PRL分泌亢進症 Prolactin secreting pituitary adenoma Clinical trials / Disease details

臨床試験数 : 19 / 薬物数 : 28 - (DrugBank : 10) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 65

diseases per page:

Showing 1 to 10 of 19 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200056078	2022-03-01	2022-01-31	Germinated barley (Maiya) plus bromocriptine in prolactinoma	Germinated barley (Maiya) plus bromocriptine in prolactinoma, a randomized clinical trial	prolactinoma	Group A:Germinated barley (Maiya) plus bromocriptine;Group B:Bromocriptine;	Huashan Hospital	NULL	Pending	18	70	Both	Group A:30;Group B:30;		China
2	NCT04107480 (ClinicalTrials.gov)	June 21, 2019	27/8/2019	PRolaCT - Three Prolactinoma RCTs	PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials	Prolactinoma;Prolactin-Producing Pituitary Tumor	Procedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine Agonists	Leiden University Medical Center	NULL	Recruiting	18 Years	N/A	All	880	Phase 4	Netherlands
3	NCT03717454 (ClinicalTrials.gov)	December 1, 2018	14/10/2018	Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D ...	Prolactinoma	Other: Surgery;Drug: Drug treatment	Zhebao Wu	Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;Fi ...	Not yet recruiting	18 Years	65 Years	All	50	N/A	NULL
4	NCT03400865 (ClinicalTrials.gov)	October 25, 2018	8/1/2018	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Pr ...	Resistance, Disease;Prolactinoma	Drug: HCQ/CQ and CAB combined treatment	Zhebao Wu	Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;Fi ...	Not yet recruiting	18 Years	70 Years	All	30	N/A	China
5	NCT03457389 (ClinicalTrials.gov)	February 22, 2018	23/1/2018	Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ...	Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ...	Pituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence Tumor	Drug: Cabergoline	Seoul National University Hospital	NULL	Recruiting	19 Years	N/A	All	68	N/A	Korea, Republic of
6	NCT03038308 (ClinicalTrials.gov)	September 16, 2016	30/1/2017	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation ...	Hyperprolactinemia;Prolactinoma	Drug: Ropinirole	Columbia University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Active, not recruiting	18 Years	70 Years	All	23	Phase 1/Phase 2	United States
7	NCT03353025 (ClinicalTrials.gov)	January 1, 2016	20/2/2017	Study on Therapy of Non-invasive Prolactinoma	Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasiv ...	Prolactinoma	Procedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatment	First Affiliated Hospital, Sun Yat-Sen University	NULL	Recruiting	18 Years	60 Years	All	394	N/A	China
8	ChiCTR-ONC-12002194	2012-05-01	2012-05-22	Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function aft ...	Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function aft ...	prolactinoma	patients with prolactinoma:treatment with bromocriptine ;	First affiliated hospital of Sun Yat-sen University	NULL	Completed	13	55	Both	patients with prolactinoma:40;		NULL
9	NCT01344291 (ClinicalTrials.gov)	July 2011	18/4/2011	Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prol ...		Hyperprolactinoma	Drug: Curcumin	Mashhad University of Medical Sciences	NULL	Recruiting	20 Years	45 Years	Female	30	Phase 1	Iran, Islamic Republic of
10	NCT01088763 (ClinicalTrials.gov)	March 2010	16/3/2010	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tum ...	A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WIT ...	Childhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhoo ...	Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biom ...	National Cancer Institute (NCI)	NULL	Terminated	1 Year	21 Years	Both	129	Phase 1	United States;Canada

First Previous1 2Next Last